NCT06924606 Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
| NCT ID | NCT06924606 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Condition | Advanced NSCLC |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2025-07-15 |
| Primary Completion | 2026-06-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 66 participants in total. It began in 2025-07-15 with a primary completion date of 2026-06-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) NSCLC that is not amenable to radical surgery or radical radiochemotherapy, or Metastatic or recurrent NSCLC. 2. Subjects with unresectable locally advanced or metastatic or recurrent NSCLC who have failed first-line treatment with PD-1/PD-L1 inhibitors combined with platinum-based doublet chemotherapy (excluding docetaxel); or who have failed sequential first- and second-line treatment with PD-1/PD-L1 inhibitors followed by platinum-based doublet chemotherapy (excluding docetaxel). 3. Subjects must have at least one measurable lesion according to RECIST v1.1. Exclusion Criteria: 1. Histopathologically or cytopathologically confirmed to have combined neuroendocrine component. 2. Sensitivity mutation of EGFR or ALK fusion. 3. Tumor encircles important blood vessels or has obvious necrosis and air space, and the investigator considers that it may cause hemorrhage risk.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06924606 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Advanced NSCLC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06924606 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06924606 currently recruiting?
Yes, NCT06924606 is actively recruiting participants. Contact the research team at xiaojun_wang@junshipharma.com for enrollment information.
Where is the NCT06924606 trial being conducted?
This trial is being conducted at Beijing, China, Jilin, China, Hunan, China, Sichuan, China and 11 additional locations.
Who is sponsoring the NCT06924606 clinical trial?
NCT06924606 is sponsored by Shanghai Junshi Bioscience Co., Ltd.. The trial plans to enroll 66 participants.